Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
601.00    -8.00 (-1.31%)
Bid:
601.00
Ask:
604.00
Spread: 3.00 (0.499%)
Market Cap: £523.62m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Market Update

7 Apr 2020 07:00

RNS Number : 9729I
Victrex PLC
07 April 2020
 

 

 

 

 

 

 

 

7 April 2020

 

Victrex plc - market update

 

 'Solid H1 trading, strong financial position, proactive actions on COVID-19'

Victrex plc, an innovative world leader in high performance polymer solutions, today announces a market update covering trading, its financial position and proactive actions on COVID-19.

H1 trading

Trading for the first half year has been solid and in line with expectations:

· Solid volume growth, including a strong finish in March

· Good growth in Automotive and Medical, with a stable performance in Aerospace, Electronics and Value-Added Resellers, offset by weakness in Energy

· H1 2020 inventory c£100m, with high sales stock across US, Europe and Asia; appropriate raw material inventory in the UK and supply chain functioning well

Strong financial position

Victrex is part of multiple supply chains, many of which are supporting critical applications, for example in Medical. The Group retains a strong balance sheet to maintain customer, supplier and investor confidence and to ensure it has sufficient resources to invest and underpin future growth:

· The Group has facilities of £40m, comprising a committed and undrawn RCF of £20m and a £20m accordion, to October 2024

· Net cash position on 31 March of £42.2m, after payment of FY19 final dividend in February

Whilst Victrex benefits from a net cash position, we are acutely aware of the near-term uncertainty at a macro and end-market level, and have prudently implemented appropriate measures to reduce cost and conserve cash, whilst maintaining strong service levels for customers:

· Capital expenditure for UK debottlenecking programme now deferred to FY 2021

· Other capital programmes limited to essential only expenditure

· Operating cost items being limited to prioritise and support customer related activity

· China capacity investment continuing on plan

Other cash conservation measures will remain under review, which could include future shareholder dividends.

 

 

 

Proactive actions on COVID-19

The safety and well-being of Victrex employees continues to be our highest priority. We established a COVID-19 committee at the start of 2020, with a proactive approach and a range of contingency plans already implemented:

· People: we continue to follow governmental or state guidance wherever we operate

· Customers: we continue to serve customers from home offices, with all of our global employees' homeworking, wherever roles are not production related

· Essential industry: the UK government defines Chemicals as an essential industry with essential workers, with Victrex also having a long-standing history in supporting many critical and "life-sustaining" applications, particularly in Medical

o UK operations: reflecting government guidance and requirements in many "life-sustaining" applications, we are continuing to produce aligned to demand, supplemented by high buffer inventory if required

o US operations: we continue to operate on an ongoing modified basis, defined as being a 'life-sustaining' organisation in several states

· Ventilators: in addition to companies we already serve, we are supplying materials for Ventilators or related equipment to a number of global companies

Outlook

Although trading has remained in line with expectations year-to-date and the third quarter has shown early signs of a solid start, including some normal demand returning across parts of Asia, the macro-economic and end-market outlook over the coming months is very uncertain, particularly for Europe and the US.

It is therefore too early to provide guidance for the remainder of the current financial year. We will continue to produce for essential business, monitoring appropriate guidelines and assessing other cash conservation measures as required.

Victrex will report its interim results on 11 May 2020.

 

About Victrex:

 

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications which contain our materials - from smartphones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com or follow us on LinkedIn and Twitter @victrexir

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications

+44 (0) 7809 595831

 

Jakob Sigurdsson, Chief Executive

+44 (0) 1253 897700

 

Richard Armitage, Group Finance Director

+44 (0) 1253 897700

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFLDSVIRIII
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.